ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions-but there is always room for improvement.

It has been 20 years since the term “genome editing” first entered the scientific lexicon, a field that was revolutionized by the development of CRISPR gene editing in 2012. But the remarkable ...

Under the terms of the arrangement, EditCo will incorporate Promega’s bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines. According to the partners ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from the preceding trading day. Gene therapy developer CRISPR Therapeutics AG ...

The global Humanized Mouse and Rat Model Market, valued at US$255.8 million in 2024, is forecasted to grow at a robust CAGR ...

ToolGen, Inc. (KOSDAQ 199800), led by CEO Jong Sang Ryu and recognized as a global leader in genome editing technology, announced today that it has filed a patent infringement lawsuit in the United ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...